ABOS

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

Retrieved on: 
Friday, March 8, 2024

CHARLOTTESVILLE, Va., March 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today presented cerebrospinal fluid (CSF) biomarker data from the sabirnetug (ACU193) Phase 1 INTERCEPT-AD trial in an oral presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) in Lisbon, Portugal, and online. Acumen also presented a poster showcasing the method used to develop a first-of-its-kind assay to measure target engagement of an AβO-selective antibody.

Key Points: 
  • Acumen also presented a poster showcasing the method used to develop a first-of-its-kind assay to measure target engagement of an AβO-selective antibody.
  • Acumen’s sabirnetug is the first humanized monoclonal antibody to clinically demonstrate selective target engagement of AβOs, a soluble and highly toxic form of Aβ that accumulates early in AD and triggers synaptic dysfunction and neurodegeneration.
  • Positive topline results from 62 participants dosed in the Phase 1 INTERCEPT-AD trial (NCT04931459) were reported in July 2023 , and additional insights from exploratory analyses have further confirmed sabirnetug’s proof-of-mechanism and broad therapeutic potential as a next-generation treatment for early AD.
  • The novel assay configuration was tailored to selectively detect sabirnetug-AβO complex in CSF as a direct measure of target engagement, showing clear dose-related increases in target engagement across all cohorts.

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

Retrieved on: 
Wednesday, February 21, 2024

CHARLOTTESVILLE, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it will be presenting biomarker data and target engagement methods in an oral and poster presentation, respectively, at the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD), taking place March 5-9, 2024, in Lisbon, Portugal, and online.

Key Points: 
  • Acumen’s sabirnetug (ACU193) is the first humanized monoclonal antibody to demonstrate selective target engagement of AβOs, a soluble and highly toxic form of Aβ that accumulates early in AD and triggers synaptic dysfunction and neurodegeneration.
  • Positive topline results from 62 participants in the Phase 1 INTERCEPT-AD trial (NCT04931459) showed sabirnetug to be well-tolerated with a favorable overall safety profile.
  • Effects of sabirnetug on both neurogranin and pTau181 levels in CSF in this Phase 1 study are consistent with downstream pharmacologic effects of the drug.
  • Presentation details as follows:
    Sabirnetug is the nonproprietary name for ACU193 accepted by USAN and INN.

The Inner Circle Acknowledges, Brian A. Murphy as a Pinnacle Lifetime Member

Retrieved on: 
Friday, March 1, 2024

NAPERVILLE, Ill., March 1, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Brian A. Murphy is acknowledged as a Pinnacle Lifetime Member for his contributions to the Orthopedic Surgeon Industry.

Key Points: 
  • NAPERVILLE, Ill., March 1, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Brian A. Murphy is acknowledged as a Pinnacle Lifetime Member for his contributions to the Orthopedic Surgeon Industry.
  • His dedication to informed and collaborative patient care sets him apart in the field of orthopedic surgery.
  • Furthering his scholarship, Dr. Murphy also earned a Master of Business Administration degree from the University of Massachusetts.
  • Looking ahead, Dr. Murphy remains dedicated to providing the highest quality orthopedic care, emphasizing informed and collaborative patient partnerships.

Paul Tornetta III, MD, PhD, FAAOS, Named 92nd President of the American Academy of Orthopaedic Surgeons

Retrieved on: 
Wednesday, February 14, 2024

SAN FRANCISCO, Feb. 14, 2024 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announced Boston orthopaedic trauma surgeon Paul Tornetta III, MD, PhD, FAAOS, as its new president for 2024-2025.

Key Points: 
  • SAN FRANCISCO, Feb. 14, 2024 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announced Boston orthopaedic trauma surgeon Paul Tornetta III, MD, PhD, FAAOS, as its new president for 2024-2025.
  • In his acceptance speech, Dr. Tornetta said, "I am honored and humbled to serve as AAOS president.
  • As orthopaedic surgeons, we share a strong bond based in helping others.
  • He is past president of the Orthopaedic Trauma Association (OTA) and served on the executive committee of the American Orthopaedic Association (AOA) for more than a decade.

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

Retrieved on: 
Thursday, February 1, 2024

CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today the appointment of James Doherty, Ph.D., as President and Chief Development Officer, effective February 1, 2024, reporting to Daniel O’Connell, Chief Executive Officer.

Key Points: 
  • CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today the appointment of James Doherty, Ph.D., as President and Chief Development Officer, effective February 1, 2024, reporting to Daniel O’Connell, Chief Executive Officer.
  • Dr. Doherty’s responsibilities will include oversight of clinical and non-clinical development, chemistry, manufacturing & controls and regulatory functions.
  • “We are extremely excited to welcome Jim, who brings extensive experience and demonstrated leadership abilities in CNS drug development to Acumen,” Mr. O’Connell said.
  • Prior to joining Acumen, Dr. Doherty served as Chief Development Officer at Sage Therapeutics, where the team achieved U.S. Food and Drug Administration approvals of two treatments for postpartum depression.

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024

CHARLOTTESVILLE, Va., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11, 2024, at 10:30 a.m. PT (1:30 p.m.

Key Points: 
  • CHARLOTTESVILLE, Va., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11, 2024, at 10:30 a.m. PT (1:30 p.m.
  • ET).
  • The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

Retrieved on: 
Monday, November 13, 2023

“We are pleased to announce this agreement with K2 HealthVentures, a life sciences investment firm known for strategic investments in promising healthcare companies,” said Daniel O’Connell, President and Chief Executive Officer of Acumen.

Key Points: 
  • “We are pleased to announce this agreement with K2 HealthVentures, a life sciences investment firm known for strategic investments in promising healthcare companies,” said Daniel O’Connell, President and Chief Executive Officer of Acumen.
  • “This financing provides us with additional operational flexibility during a period when we are laser-focused on execution.
  • The Term Loan matures on November 1, 2027 and may be extended to November 1, 2028 if the Company achieves certain financing milestones.
  • Additional details regarding the Loan Agreement will be included in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Monday, November 13, 2023

ET

Key Points: 
  • ET
    CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the third quarter of 2023 and provided a business update.
  • “We have also observed encouraging trends in CSF biomarker data from our Phase 1 study, further solidifying the pharmacology of ACU193.
  • In October 2023, the Company met with the FDA to discuss the next clinical trial in the development program for ACU193.
  • Acumen will host a conference call and live audio webcast today, Nov. 13, 2023, at 8:00 a.m.

The Inner Circle Acknowledges, Douglas R. Adams as a Pinnacle Lifetime Member for his contributions to the field of Orthopedic Surgery

Retrieved on: 
Monday, December 4, 2023

COLORADO SPRINGS, Colo., Dec. 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Douglas R. Adams is acknowledged as a Pinnacle Lifetime Member for his contributions to the field of Orthopedic Surgery.

Key Points: 
  • COLORADO SPRINGS, Colo., Dec. 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Douglas R. Adams is acknowledged as a Pinnacle Lifetime Member for his contributions to the field of Orthopedic Surgery.
  • A highly respected orthopedic surgeon, Dr. Adams is affiliated with Colorado Orthopedic Specialists, a part of the HealthONE Physician Group.
  • He is a specialist in hip arthroscopy and hip preservation surgery; sports medicine and arthroscopic surgery; and robotic total joint replacement surgery.
  • Dr. Adams noted that orthopedic surgery is a specialized branch of surgery focused on conditions related to the musculoskeletal system.

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Retrieved on: 
Tuesday, November 7, 2023

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 14, 2023 at 2:25 p.m.

Key Points: 
  • CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 14, 2023 at 2:25 p.m.
  • ET.
  • The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.